Idacio®
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Psoriasic arthritis
Ulcerative colitis
Crohn's disease
Psoriasis
Ankylosing spondylitis
Hidradenitis suppurativa
Uveitis
DATE:
02/04/2019
STATUS:
Authorized